Español
PDFs by language
Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Call us at 1-800-227-2345
Available any time of day or night
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
As researchers have learned more about the changes inside cells that cause them to become cancer cells, they have developed newer drugs that target some of these changes. These targeted drugs work differently from other types of treatment, such as chemotherapy (chemo). They may work in some cases when other treatments don't. Targeted drugs also often have different types of side effects.
Fibroblast growth factor receptors (FGFRs) are a group of proteins on bladder cancer cells that can help them grow. In some bladder cancers, the cells have changes in FGFR genes, which are the genes that control how much of the FGFR proteins are made. Drugs that target cells with FGFR gene changes (called FGFR inhibitors) can help treat some people with bladder cancer.
This FGFR inhibitor can be used to treat advanced bladder cancer that has certain changes detected in the FGFR3 gene, and that is still growing despite treatment with other drugs, such as chemo. This drug isn’t usually given to people who are eligible for but haven’t yet received an immune checkpoint inhibitor.
Erdafitinib is taken by mouth as tablets, typically once a day.
Common side effects of erdafitinib include mouth sores, feeling tired, changes in kidney or liver function, diarrhea, dry mouth, changes in fingernails or toenails, changes in mineral levels in the blood (such as phosphate and sodium), loss of appetite, changes in how things taste, low red blood cell counts (anemia), dry skin, dry eyes, and hair loss.
Other side effects can include hand-foot syndrome (redness, swelling, peeling or tenderness on the hands or feet), constipation, belly pain, nausea, and muscle pain.
This drug can also cause eye problems, which can sometimes be serious, so people taking this drug need to have regular eye exams and should tell their health care provider right away if they have blurred vision, loss of vision, or other visual changes.
Antibody-drug conjugates (ADCs) might also be considered a form of targeted therapy. These medicines are made up of a chemo drug linked to a monoclonal antibody, which is a lab-made version of an immune system protein that’s designed to attach to a specific target on cancer cells. Once inside the body, the antibody part of the ADC acts like a homing device, bringing the chemo directly to the cancer cells.
ADCs that can be used to treat bladder cancer include:
For more on these drugs, see Immunotherapy for Bladder Cancer.
To learn more about how targeted drugs are used to treat cancer, see Targeted Cancer Therapy.
To learn about some of the side effects listed here and how to manage them, see Managing Cancer-related Side Effects.
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.
Bellmunt J. Treatment of metastatic urothelial cancer of the bladder and urinary tract. UpToDate. 2023. Accessed at https://www.uptodate.com/contents/treatment-of-metastatic-urothelial-cancer-of-the-bladder-and-urinary-tract on November 14, 2023.
National Cancer Institute. Bladder Cancer Treatment (PDQ)–Health Professional Version. 2023. Accessed at https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq on November 14, 2023.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 3.2023. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf on November 14, 2023.
Last Revised: March 12, 2024
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.
If this was helpful, donate to help fund patient support services, research, and cancer content updates.